NCT00372008已完成2 期
A Phase II Randomised, Two-Way Crossover Study to Compare the Steady State Pharmacokinetics of Testosterone Following Application of Different Testosterone Metered-Dose (MD) Lotion Doses in Hypogonadal Male Subjects
适应症
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 40
- 试验地点
- 7
- 主要终点
- Pharmacokinetic
研究概览
简要总结
Testosterone replacement treatment is the most effective way of treating hypogonadism in men. Acrux has a proprietry testosterone replacement product - Testosterone-MD Lotion, and this study will evaluate the efficacy and safety of this product.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Crossover
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 70 Years（Adult, Older Adult）
- 性别
- Male
- 接受健康志愿者
- 否
入选标准
- •Hypogonadal males between 18-70 years old with qualifying general medical health
排除标准
- •Disqualifying concurrent conditions or allergy/sensitivity to testosterone replacement therapy
结局指标
主要结局
Pharmacokinetic
次要结局
- Safety and tolerability
研究者
研究点 (7)
Loading locations...
相似试验
已完成
2 期
A Study of the Pharmacokinetics of Testosterone Metered Dose (MD)-Lotion FormulationsHypogonadismNCT00857961Eli Lilly and Company21
已完成
1 期
To Determine the Effects of Deodorant, Antiperspirant and Washing on the Pharmacokinetics of 2% Testosterone MD LotionHypogonadismNCT00857168Acrux DDS Pty Ltd36
已完成
3 期
A Titration Trial to Determine the Effectiveness of Testosterone MD-Lotion (Cutaneous Solution) FormulationsHypogonadismNCT00702650Eli Lilly and Company155
已完成
3 期
A Trial to Evaluate the Ongoing Skin Safety of Testosterone MD-Lotion FormulationsHypogonadismNCT00857454Eli Lilly and Company71
已完成
2 期
28-Day Study of Testosterone Co-administered With Dutasteride in Hypogonadal MenHypogonadismHypogonadism, MaleNCT00398580GlaxoSmithKline43